Company intelligence / Profile preview

Sanifit Therapeutics

Palma de Mallorca, Balearic Islands, Spain

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Sanifit's lead candidate, SNF472, demonstrated positive results in Phase II studies for calciphylaxis and cardiovascular calcification. The drug received orphan drug designation from both the FDA and EMA. At the time of its acquisition by Vifor Pharma in late 2021, a pivotal Phase III trial for CUA was underway and a Phase II study targeting PAD was planned to start mid–2022. No approved therapies exist for these indications.

Therapeutic areas: CardiovascularNephrology
Modalities: Small molecules (lead asset SNF472)
Industry: Biotech

Partnerships

No major disclosed pharma partnerships prior to acquisition; post-acquisition development under Vifor Pharma umbrella

Beyond the preview

Go deeper on Sanifit Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanifit Therapeutics.

Explore the full profile